MaxCyte (NASDAQ:MXCT) Issues Earnings Results, Beats Expectations By $0.04 EPS

MaxCyte (NASDAQ:MXCT) posted its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04, Zacks reports. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%.

MaxCyte Price Performance

Shares of NASDAQ:MXCT traded up $0.05 during trading on Tuesday, reaching $3.47. 569,560 shares of the stock were exchanged, compared to its average volume of 592,048. MaxCyte has a 1-year low of $3.16 and a 1-year high of $5.26. The stock has a fifty day moving average of $4.25 and a two-hundred day moving average of $4.00. The firm has a market cap of $367.68 million, a price-to-earnings ratio of -10.21 and a beta of 1.35.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.